^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SAIL66

    i
    Other names: SAIL66
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CD3 agonist, CD137 agonist, CLDN6 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=178, Recruiting, Chugai Pharmaceutical | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    Actemra IV (tocilizumab) • SAIL66
    1year
    A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=178, Not yet recruiting, Chugai Pharmaceutical
    New P1 trial • Metastases
    |
    CLDN6 (Claudin 6)
    |
    CLDN6 positive
    |
    Actemra IV (tocilizumab) • SAIL66